nadroparin calcium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5162	37270-89-6

Description:

Molecule	Description
Synonyms: nadroparin nadroparin calcium fraxiparine fraxiparin	A low molecular weight heparin (LMWH) composed of a heterogeneous mixture of sulfated polysaccharide glycosaminoglycan chains obtained by depolymerisation of porcine mucosal sodium heparin, extraction/purification and conversion to the calcium salt. Nadroparin binds to antithrombin III (ATIII) and inhibits the activity of activated factor X (factor Xa), thereby inhibiting the final common pathway of the coagulation cascade and preventing the formation of a cross-linked fibrin clot Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

nadroparin
nadroparin calcium
fraxiparine
fraxiparin

A low molecular weight heparin (LMWH) composed of a heterogeneous mixture of sulfated polysaccharide glycosaminoglycan chains obtained by depolymerisation of porcine mucosal sodium heparin, extraction/purification and conversion to the calcium salt. Nadroparin binds to antithrombin III (ATIII) and inhibits the activity of activated factor X (factor Xa), thereby inhibiting the final common pathway of the coagulation cascade and preventing the formation of a cross-linked fibrin clot

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
2.85	TU	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
None	Health Canada

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Lymphatic fistula	96.53	25.37	20	4767	766	63483469
Femoral hernia incarcerated	95.18	25.37	20	4767	821	63483414
Pancreatic steatosis	91.42	25.37	20	4767	996	63483239
Wound dehiscence	89.30	25.37	27	4760	4876	63479359
Wound infection pseudomonas	86.08	25.37	20	4767	1308	63482927
Arterial haemorrhage	86.04	25.37	21	4766	1696	63482539
Seroma	81.54	25.37	21	4766	2110	63482125
Haemarthrosis	73.33	25.37	21	4766	3140	63481095
Aortic valve stenosis	72.45	25.37	21	4766	3278	63480957
Premature baby	72.38	25.37	34	4753	20701	63463534

Showing 1 to 10 of 44 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary embolism	47.05	22.77	49	3146	89697	34864039
Suture rupture	41.16	22.77	9	3186	367	34953369
Herpes zoster reactivation	31.76	22.77	7	3188	296	34953440
Erysipelas	31.36	22.77	13	3182	4850	34948886
Soft tissue disorder	30.16	22.77	8	3187	742	34952994
Lymphocele	29.70	22.77	9	3186	1348	34952388
Umbilical hernia	28.47	22.77	12	3183	4665	34949071
Device related infection	27.46	22.77	18	3177	17219	34936517
Autoimmune disorder	27.22	22.77	9	3186	1785	34951951
Acetabulum fracture	26.40	22.77	6	3189	292	34953444

Showing 1 to 10 of 15 entries

Previous1 2Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Lymphatic fistula	92.02	19.58	20	7353	783	79736232
Femoral hernia incarcerated	91.08	19.58	20	7353	822	79736193
Wound dehiscence	87.55	19.58	30	7343	6565	79730450
Pancreatic steatosis	84.96	19.58	20	7353	1125	79735890
Wound infection pseudomonas	78.05	19.58	20	7353	1601	79735414
Seroma	75.69	19.58	21	7352	2279	79734736
Arterial haemorrhage	73.45	19.58	21	7352	2540	79734475
Tachyarrhythmia	63.53	19.58	24	7349	6938	79730077
Aortic valve stenosis	58.46	19.58	21	7352	5273	79731742
Haemarthrosis	56.54	19.58	21	7352	5791	79731224

Showing 1 to 10 of 58 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	B01AB06	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Heparin group
MeSH PA	D000925	Anticoagulants
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D005343	Fibrinolytic Agents
MeSH PA	D006401	Hematologic Agents

Showing 1 to 5 of 5 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Deep venous thrombosis	indication	128053003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
005821	NDDF
005822	NDDF
5750	INN_ID
67031	RXNORM
698278006	SNOMEDCT_US
699946002	SNOMEDCT_US
772	PUBCHEM_CID
773473005	SNOMEDCT_US
9005-49-6	SECONDARY_CAS_RN
C0206232	UMLSCUI

Showing 1 to 10 of 14 entries

Previous1 2Next

Pharmaceutical products:

None